REG - Versarien PLC - Appointment of Chief Technology Officer

VersarienAnnouncement

07/01/2021 07:02

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210107:nRSG8324Ka&default-theme=true

RNS Number : 8324K  Versarien PLC  07 January 2021

7 January 2021

Versarien plc

("Versarien" or the "Company")

Appointment of Chief Technology Officer

Versarien plc (AIM: VRS), the advanced materials engineering group, is pleased
to announce that Dr Stephen Hodge has been appointed as the Company's Chief
Technology Officer ("CTO") and has joined the Company's Board with immediate
effect.

 

Dr Hodge is currently Head of Research at Versarien, a role he has held since
July 2018. Prior to this, he was employed as a Principal Engineer at Cambridge
Graphene Limited, a supplier of graphene inks and other graphene materials,
and a subsidiary of Versarien. He has also held post-doctoral research
associate positions at the Cambridge Graphene Centre, a research centre
attached to the Department of Engineering at the University of Cambridge, and
in the Department of Chemistry at Imperial College London, where he also
completed a PhD in Nanomaterial Chemistry.

 

Stephen is a member of the International Advisory Board for the Graphene
NOWNANO CDT at the University of Manchester and was formerly a Teaching Fellow
in the EPSRC Centre for Doctoral Training (CDT) program in Graphene Technology
at The University of Cambridge. Stephen also holds the role of Chairman of the
Technical Working Group within the Graphene REACH registration consortium.

 

Following Dr Hodge's appointment, the Company's Board now comprises James
Stewart (Non-executive Chairman), Neill Ricketts (CEO), Christopher Leigh
(CFO), Stephen Hodge (CTO), Susan Bowen (Non-executive Director) and Iain Gray
(Non-executive Director).

 

Neill Ricketts, CEO of Versarien, commented: "We are delighted to welcome
Steve to the Versarien Board. He brings significant research and scientific
experience to the CTO role and will be responsible for developing solutions
and creating partnerships with the Graphene and Plastics division's commercial
pipeline.

 

"His academic credentials are impeccable and his time as Head of Research at
Versarien ensures that Steve will continue to contribute to the progression of
our commercial partnerships and international expansion strategy."

 

Further information on Dr Stephen Hodge

 

Dr Stephen Anthony Hodge, aged 34, holds no other current directorships or
partnerships and has no former directorships or partnerships within the last
five years.

 

Dr Hodge does not hold any ordinary shares of the Company. As part of his
existing remuneration package, Dr Hodge has been previously granted share
options over the Company's ordinary shares as follows:

 

a)    453,720 share options with an exercise price of 117p per share
expiring in December 2028; and

b)    75,000 share options with an exercise price of 21.25p per share
expiring in April 2027.

 

Save as disclosed above, there are no additional disclosures to be made in
accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.

 

Enquiries:

 Versarien                                                            +44 (0)1242 269 122

 Neill Ricketts, CEO

 Chris Leigh, CFO
 SP Angel Corporate Finance (Nominated Adviser and Joint Broker)      +44 (0)20 3470 0470

 Matthew Johnson, Ewan Leggat, Adam Cowl

 Berenberg (Joint Broker)                                             +44 (0)20 3207 7800

 Mark Whitmore, Simon Cardron
 Yellow Jersey (Investor Relations)                                   +44 (0)774 778 8221

 Charles Goodwin

 Georgia Colkin

 Henry Wilkinson

 Versarien@yellowjerseypr.com (mailto:Versarien@yellowjerseypr.com)

 

Notes to Editors:

 

Versarien Plc (AIM:VRS), is an advanced engineering materials group.
Leveraging proprietary technology, the Group creates innovative engineering
solutions for its clients in a diverse range of industries.

 

For further information please see: http://www.versarien.com
(http://www.versarien.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDKABQABKDADK